SCHEMBL124177

SCHEMBL124177

O=C1[CH]c2ccccc2N1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
GAA P10253 2/20 0.50
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
PDGFRA P16234 1/20 0.38
FER P16591 1/20 0.38
LTK P29376 1/20 0.38
CDK8 P49336 1/20 0.38
ACVR1 Q04771 1/20 0.38
LRRK2 Q5S007 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
PDK2 Q15119 2/20 0.37
AHR P35869 1/20 0.37
NPC1 O15118 1/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
PDK4 Q16654 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4787144 1.00 MAPT (0.50) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL3942968 0.82 LRRK2 (0.47) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL1087950 0.78 GAA (0.68) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL7440281 0.75 MAPT (0.56) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL7440282 0.75 MAPT (0.56) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL5710944 0.73 GAA (0.43) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL5710948 0.73 GAA (0.43) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL8874013 0.70 GSK3B (0.56) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL8874017 0.70 GSK3B (0.56) MAPTGAAMAOAMAOBPDGFRA
SCHEMBL6204410 0.69 MAPT (0.48) MAPTGAAMAOAMAOBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112258-A1 SEROTONIN RECEPTOR AS A TARGET FOR THERAPY AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2024-05-30 WO claimed
EP-3805210-B1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AUTOPHAGYSCIENCES INC (KR) 2023-11-29 EP claimed
US-20220220106-A1 QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2022-07-14 US claimed
CN-113767099-A Quinoline compound, and medicinal composition and application thereof 中国人民解放军军事科学院军事医学研究院 2021-12-07 CN claimed
US-11168073-B2 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-11-09 US claimed
EP-3288942-B1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2021-10-27 EP claimed
CN-107660205-B Heterocyclic compounds as LSD1 inhibitors 因赛特公司 2021-08-27 CN claimed
CN-113286794-A KRAS mutein inhibitors 北京加科思新药研发有限公司 2021-08-20 CN claimed
US-11084826-B2 RSV antiviral pyrazolo- and triazolo-pyrimidine compounds Janssen Sciences Ireland Unlimited Company (IE) 2021-08-10 US claimed
EP-3805210-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Autophagysciences, Inc (KR) 2021-04-14 EP claimed
WO-1995033721-A1 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES H. LUNDBECK A/S (DK) 1995-12-14 WO claimed
EP-0221958-B1 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Louis, William John (AU) 1992-10-28 EP claimed
EP-0442878-A4 DERIVATIVES OF TRYPTOPHAN AS CCK ANTAGONISTS 1991-10-23 EP claimed
EP-0442878-A1 DERIVATIVES OF TRYPTOPHAN AS CCK ANTAGONISTS ABBOTT LABORATORIES (US) 1991-08-28 EP claimed
US-4977153-A BETA ADRENOCEPTOR BLOCKING AGENTS Louis, William J. (AU) 1990-12-11 US claimed
WO-1989010355-A1 DERIVATIVES OF TRYPTOPHAN AS CCK ANTAGONISTS ABBOTT LABORATORIES (US) 1989-11-02 WO claimed
EP-0336356-A2 Derivatives of tryptophan as CCK antagonists ABBOTT LABORATORIES (US) 1989-10-11 EP claimed
EP-0221958-A4 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. LOUIS WILLIAM JOHN (AU) 1987-11-25 EP claimed
EP-0221958-A1 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. LOUIS WILLIAM JOHN (AU) 1987-05-20 EP claimed
WO-1986006717-A1 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LOUIS WILLIAM JOHN (AU) 1986-11-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168073-B2 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same VAPA, VAPB, SLC10A1 MAPT 2179/4885GAA 441/4885MAOA 883/4885
US-11084826-B2 RSV antiviral pyrazolo- and triazolo-pyrimidine compounds ZC3HAV1, MAVS, TYMP MAPT 3325/4885GAA 2343/4885MAOA 2699/4885
US-20220220106-A1 QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF MTOR, RICTOR, EIF4E MAPT 1257/4885GAA 811/4885MAOA 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.